OBJECTIVE: To determine whether amyloid imaging with the positron emission tomography (PET) agent Pittsburgh compound B (PiB) can detect vascular β-amyloid (Aβ) in the essentially pure form of cerebral amyloid angiopathy associated with the Dutch-type hereditary cerebral amyloid angiopathy (D-CAA) mutation. METHODS: PiB retention in a cortical composite of frontal, lateral, and retrosplenial regions (FLR) was measured by PiB-PET in 19 D-CAA mutation carriers (M+ ; 13 without neurologic symptoms, 6 with prior lobar intracerebral hemorrhage) and 17 mutation noncarriers (M- ). Progression of PiB retention was analyzed in a subset of 18 serially imaged individuals (10 asymptomatic M+ , 8 M- ). We also analyzed associations between PiB retention and cerebrospinal fluid (CSF) Aβ concentrations in 17 M+ and 11 M- participants who underwent lumbar puncture and compared the findings to PiB-PET and CSF Aβ in 37 autosomal dominant Alzheimer disease (ADAD) mutation carriers. RESULTS: D-CAA M+ showed greater age-dependent FLR PiB retention (p < 0.001) than M- , and serially imaged asymptomatic M+ demonstrated greater longitudinal increases (p = 0.004). Among M+ , greater FLR PiB retention associated with reduced CSF concentrations of Aβ40 (r = -0.55, p = 0.021) but not Aβ42 (r = 0.01, p = 0.991). Despite comparably low CSF Aβ40 and Aβ42, PiB retention was substantially less in D-CAA than ADAD (p < 0.001). INTERPRETATION: Increased PiB retention in D-CAA and correlation with reduced CSF Aβ40 suggest this compound labels vascular amyloid, although to a lesser degree than amyloid deposits in ADAD. Progression in PiB signal over time suggests amyloid PET as a potential biomarker in trials of candidate agents for this untreatable cause of hemorrhagic stroke. ANN NEUROL 2019;86:616-625.
OBJECTIVE: To determine whether amyloid imaging with the positron emission tomography (PET) agent Pittsburgh compound B (PiB) can detect vascular β-amyloid (Aβ) in the essentially pure form of cerebral amyloid angiopathy associated with the Dutch-type hereditary cerebral amyloid angiopathy (D-CAA) mutation. METHODS:PiB retention in a cortical composite of frontal, lateral, and retrosplenial regions (FLR) was measured by PiB-PET in 19 D-CAA mutation carriers (M+ ; 13 without neurologic symptoms, 6 with prior lobar intracerebral hemorrhage) and 17 mutation noncarriers (M- ). Progression of PiB retention was analyzed in a subset of 18 serially imaged individuals (10 asymptomatic M+ , 8 M- ). We also analyzed associations between PiB retention and cerebrospinal fluid (CSF) Aβ concentrations in 17 M+ and 11 M- participants who underwent lumbar puncture and compared the findings to PiB-PET and CSF Aβ in 37 autosomal dominant Alzheimer disease (ADAD) mutation carriers. RESULTS: D-CAA M+ showed greater age-dependent FLR PiB retention (p < 0.001) than M- , and serially imaged asymptomatic M+ demonstrated greater longitudinal increases (p = 0.004). Among M+ , greater FLR PiB retention associated with reduced CSF concentrations of Aβ40 (r = -0.55, p = 0.021) but not Aβ42 (r = 0.01, p = 0.991). Despite comparably low CSF Aβ40 and Aβ42, PiB retention was substantially less in D-CAA than ADAD (p < 0.001). INTERPRETATION: Increased PiB retention in D-CAA and correlation with reduced CSF Aβ40 suggest this compound labels vascular amyloid, although to a lesser degree than amyloid deposits in ADAD. Progression in PiB signal over time suggests amyloid PET as a potential biomarker in trials of candidate agents for this untreatable cause of hemorrhagic stroke. ANN NEUROL 2019;86:616-625.
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Rebecca L McNamee; Seong-Hwan Yee; Julie C Price; William E Klunk; Bedda Rosario; Lisa Weissfeld; Scott Ziolko; Michael Berginc; Brian Lopresti; Steven Dekosky; Chester A Mathis Journal: J Nucl Med Date: 2009-02-17 Impact factor: 10.057
Authors: Marissa D Zwan; Rik Ossenkoppele; Nelleke Tolboom; Alexandra J M Beunders; Reina W Kloet; Sofie M Adriaanse; Ronald Boellaard; Albert D Windhorst; Pieter Raijmakers; Human Adams; Adriaan A Lammertsma; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel Journal: J Nucl Med Date: 2014-06-04 Impact factor: 10.057
Authors: Fen Wang; Brian A Gordon; Davis C Ryman; Shengmei Ma; Chengjie Xiong; Jason Hassenstab; Alison Goate; Anne M Fagan; Nigel J Cairns; Daniel S Marcus; Eric McDade; John M Ringman; Neill R Graff-Radford; Bernardino Ghetti; Martin R Farlow; Reisa Sperling; Steve Salloway; Peter R Schofield; Colin L Masters; Ralph N Martins; Martin N Rossor; Mathias Jucker; Adrian Danek; Stefan Förster; Christopher A S Lane; John C Morris; Tammie L S Benzinger; Randall J Bateman Journal: Neurology Date: 2015-08-05 Impact factor: 9.910
Authors: Steven M Greenberg; Thomas Grabowski; M Edip Gurol; Maureen E Skehan; R N Kaveer Nandigam; John A Becker; Monica Garcia-Alloza; Claudia Prada; Matthew P Frosch; Jonathan Rosand; Anand Viswanathan; Eric E Smith; Keith A Johnson Journal: Ann Neurol Date: 2008-11 Impact factor: 10.422
Authors: Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Jasmeer P Chhatwal; Aaron P Schultz; Gad A Marshall; Brendon Boot; Teresa Gomez-Isla; Julien Dumurgier; Molly LaPoint; Clemens Scherzer; Allyson D Roe; Bradley T Hyman; Reisa A Sperling; Keith A Johnson Journal: Neurology Date: 2016-07-29 Impact factor: 9.910
Authors: M Edip Gurol; J Alex Becker; Panagiotis Fotiadis; Grace Riley; Kristin Schwab; Keith A Johnson; Steven M Greenberg Journal: Neurology Date: 2016-09-07 Impact factor: 9.910
Authors: Pratishtha Chatterjee; Anne M Fagan; Chengjie Xiong; Matthew McKay; Atul Bhatnagar; Yunqi Wu; Abhay K Singh; Kevin Taddei; Ian Martins; Samantha L Gardener; Mark P Molloy; Gerhard Multhaup; Colin L Masters; Peter R Schofield; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Marieke J H Wermer; Mark A van Buchem; Hamid R Sohrabi; Ralph N Martins Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Stuart J McCarter; Timothy G Lesnick; Val Lowe; Michelle M Mielke; Eleni Constantopoulos; Alejandro A Rabinstein; Scott A Przybelski; Hugo Botha; David T Jones; Vijay K Ramanan; Clifford R Jack; Ronald C Petersen; David Knopman; Bradley F Boeve; Melissa E Murray; Dennis W Dickson; Prashanthi Vemuri; Kejal Kantarci; R Ross Reichard; Jonathan Graff-Radford Journal: Neurology Date: 2021-09-09 Impact factor: 9.910
Authors: Andrew N Bubak; Cheryl Beseler; Christina N Como; Christina M Coughlan; Noah R Johnson; James E Hassell; Anna M Burnet; Teresa Mescher; D Scott Schmid; Colin Coleman; Ravi Mahalingam; Randall J Cohrs; Timothy D Boyd; Huntington Potter; Ali H Shilleh; Holger A Russ; Maria A Nagel Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226
Authors: Laura Gatti; Francesca Tinelli; Emma Scelzo; Francesco Arioli; Giuseppe Di Fede; Laura Obici; Leonardo Pantoni; Giorgio Giaccone; Paola Caroppo; Eugenio Agostino Parati; Anna Bersano Journal: Int J Mol Sci Date: 2020-05-13 Impact factor: 5.923
Authors: Pratishtha Chatterjee; Michelle Tegg; Steve Pedrini; Anne M Fagan; Chengjie Xiong; Abhay K Singh; Kevin Taddei; Samantha Gardener; Colin L Masters; Peter R Schofield; Gerhard Multhaup; Tammie L S Benzinger; John C Morris; Randall J Bateman; Steven M Greenberg; Mark A van Buchem; Erik Stoops; Hugo Vanderstichele; Charlotte E Teunissen; Graeme J Hankey; Marieke J H Wermer; Hamid R Sohrabi; Ralph N Martins Journal: Int J Mol Sci Date: 2021-03-13 Impact factor: 5.923
Authors: Lieke Jäkel; Anna M De Kort; Catharina J M Klijn; Floris H B M Schreuder; Marcel M Verbeek Journal: Alzheimers Dement Date: 2021-05-31 Impact factor: 16.655